Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050668 · ClinicalTrials.gov registry record · Phase 2
Essential Amino Acid Supplementation for Femoral Fragility Fractures
A Phase 2 study of Muscle Atrophy and Femoral Fracture, sponsored by Michael C Willey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT06050668: Recruiting Phase 2 study of Muscle Atrophy and Femoral Fracture, sponsored by Michael C Willey.
NCT06050668 is a Phase 2 study of Muscle Atrophy and Femoral Fracture that is actively recruiting participants, run by Michael C Willey. The registered enrollment target is 60 participants, above the 44-participant average among 11 other Muscle Atrophy trials with a reported enrollment target (36% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06050668, a Phase 2 study of Muscle Atrophy and Femoral Fracture, is actively recruiting participants, sponsored by Michael C Willey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.
Primary Outcome
Biopsy results will provide the counts and averages by Type I and Type II fibers for satellite cells, myonuclei, M1 and M2 macrophages.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Essential Amino Acid Supplementation
Study Locations (2)
Iowa
- University of Iowa Health Care - Iowa City
Oregon
- Slocum Center for Orthopedics & Sports Medicine - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT06050668 shows while recruiting
NCT06050668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 44-participant average among 11 other Muscle Atrophy trials with a reported enrollment target (36% higher).
The record links to 3 conditions, with Muscle Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Essential Amino Acid Supplementation is the first listed.
NCT06050668 reports a single indexed study location in Iowa, Oregon.
Frequently Asked Questions
What is clinical trial NCT06050668 about?
NCT06050668 is a clinical study titled "Essential Amino Acid Supplementation for Femoral Fragility Fractures". This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce musc...
What is the current status of trial NCT06050668?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-06-17. Estimated completion is 2025-12.
What conditions does trial NCT06050668 study?
This clinical trial studies the following conditions: Muscle Atrophy, Femoral Fracture, Fragility Fracture.
What interventions are being tested in trial NCT06050668?
The interventions under investigation include: Essential Amino Acid Supplementation (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06050668?
This trial is sponsored by Michael C Willey, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050668 being conducted?
This trial has 2 study locations across Iowa, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06050668's enrollment target sits among peer trials
60 3rd of 11 higher than 8 of 11 other Muscle Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears
ACTIVE NOT RECRUITING · Phase 2
-
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
RECRUITING
-
The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
RECRUITING · NA
-
A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
-
FIT Exercise in 30d of ULLS-induced Muscle Disuse
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI